Tags

Type your tag names separated by a space and hit enter

Isolated soya protein with standardised levels of isoflavones, cotyledon soya fibres and soya phospholipids improves plasma lipids in hypercholesterolaemia: a double-blind, placebo-controlled trial of a yoghurt formulation.
Br J Nutr. 2004 Mar; 91(3):393-401.BJ

Abstract

The objective was to study whether a yoghurt containing isolated soya protein with standardised levels of isoflavones, cotyledon soya fibres and soya phospholipids is more effective in lowering total and LDL-cholesterol than a placebo. One hundred and forty-three subjects were randomised to the soya group (n 69) or to the placebo (n 74). The mean baseline levels were 7.6 and 5.1 mmol/l for total and LDL-cholesterol, respectively. Fasting serum lipoproteins were assessed five times during the 8-week intervention period, and 4 weeks thereafter. The results were analysed by a mixed model for unbalanced repeated measurements. During the intervention, there were highly significant differences in lipid-lowering effect in favour of the active soya intervention group compared with the control group. The significant differences were for total cholesterol (estimated mean difference 0.40 mmol/l; P<0.001), LDL-cholesterol (0.39 mmol/l; P<0.001), non-HDL-cholesterol (0.40 mmol/l; P<0.001) and for the total:HDL-cholesterol ratio (0.23; P=0.005). There was no difference in the effects on HDL-cholesterol, triacylglycerols or homocysteine. The lipid-lowering effect occurred within 1-2 weeks of intervention, and was not due to weight loss. The safety profile for active soya was similar to the placebo group, except for gastrointestinal symptoms, which caused a significantly higher dropout rate (fourteen v. three subjects) among the subjects taking active soya.

Authors+Show Affiliations

National Public Health Institute, Mannerheimintie 166, FIN-00300 Helsinki, Finland. pekka.puska@ktl.fiNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15005825

Citation

Puska, Pekka, et al. "Isolated Soya Protein With Standardised Levels of Isoflavones, Cotyledon Soya Fibres and Soya Phospholipids Improves Plasma Lipids in Hypercholesterolaemia: a Double-blind, Placebo-controlled Trial of a Yoghurt Formulation." The British Journal of Nutrition, vol. 91, no. 3, 2004, pp. 393-401.
Puska P, Korpelainen V, Høie LH, et al. Isolated soya protein with standardised levels of isoflavones, cotyledon soya fibres and soya phospholipids improves plasma lipids in hypercholesterolaemia: a double-blind, placebo-controlled trial of a yoghurt formulation. Br J Nutr. 2004;91(3):393-401.
Puska, P., Korpelainen, V., Høie, L. H., Skovlund, E., & Smerud, K. T. (2004). Isolated soya protein with standardised levels of isoflavones, cotyledon soya fibres and soya phospholipids improves plasma lipids in hypercholesterolaemia: a double-blind, placebo-controlled trial of a yoghurt formulation. The British Journal of Nutrition, 91(3), 393-401.
Puska P, et al. Isolated Soya Protein With Standardised Levels of Isoflavones, Cotyledon Soya Fibres and Soya Phospholipids Improves Plasma Lipids in Hypercholesterolaemia: a Double-blind, Placebo-controlled Trial of a Yoghurt Formulation. Br J Nutr. 2004;91(3):393-401. PubMed PMID: 15005825.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Isolated soya protein with standardised levels of isoflavones, cotyledon soya fibres and soya phospholipids improves plasma lipids in hypercholesterolaemia: a double-blind, placebo-controlled trial of a yoghurt formulation. AU - Puska,Pekka, AU - Korpelainen,Vesa, AU - Høie,Lars H, AU - Skovlund,Eva, AU - Smerud,Knut T, PY - 2004/3/10/pubmed PY - 2004/3/31/medline PY - 2004/3/10/entrez SP - 393 EP - 401 JF - The British journal of nutrition JO - Br J Nutr VL - 91 IS - 3 N2 - The objective was to study whether a yoghurt containing isolated soya protein with standardised levels of isoflavones, cotyledon soya fibres and soya phospholipids is more effective in lowering total and LDL-cholesterol than a placebo. One hundred and forty-three subjects were randomised to the soya group (n 69) or to the placebo (n 74). The mean baseline levels were 7.6 and 5.1 mmol/l for total and LDL-cholesterol, respectively. Fasting serum lipoproteins were assessed five times during the 8-week intervention period, and 4 weeks thereafter. The results were analysed by a mixed model for unbalanced repeated measurements. During the intervention, there were highly significant differences in lipid-lowering effect in favour of the active soya intervention group compared with the control group. The significant differences were for total cholesterol (estimated mean difference 0.40 mmol/l; P<0.001), LDL-cholesterol (0.39 mmol/l; P<0.001), non-HDL-cholesterol (0.40 mmol/l; P<0.001) and for the total:HDL-cholesterol ratio (0.23; P=0.005). There was no difference in the effects on HDL-cholesterol, triacylglycerols or homocysteine. The lipid-lowering effect occurred within 1-2 weeks of intervention, and was not due to weight loss. The safety profile for active soya was similar to the placebo group, except for gastrointestinal symptoms, which caused a significantly higher dropout rate (fourteen v. three subjects) among the subjects taking active soya. SN - 0007-1145 UR - https://www.unboundmedicine.com/medline/citation/15005825/Isolated_soya_protein_with_standardised_levels_of_isoflavones_cotyledon_soya_fibres_and_soya_phospholipids_improves_plasma_lipids_in_hypercholesterolaemia:_a_double_blind_placebo_controlled_trial_of_a_yoghurt_formulation_ L2 - https://www.cambridge.org/core/product/identifier/S0007114504000522/type/journal_article DB - PRIME DP - Unbound Medicine ER -